(Q33561179)

English

Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers (English)

1 reference

Europe PubMed Central

28 July 2017

phase II clinical trial

0 references

0 references

0 references

placebo-controlled trial

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

14

object named as

Alan W Partin

1 reference

Europe PubMed Central

28 July 2017

Sharyn D. Baker

object named as

Sharyn D Baker

11

0 references

Steven T. Piantadosi

8

object named as

Steven Piantadosi

1 reference

Europe PubMed Central

28 July 2017

Angelo M De Marzo

6

object named as

Angelo M De Marzo

1 reference

Europe PubMed Central

28 July 2017

author name string

Emmanuel S Antonarakis

1

1 reference

Europe PubMed Central

28 July 2017

Elisabeth I Heath

2

1 reference

Europe PubMed Central

28 July 2017

Janet R Walczak

3

1 reference

Europe PubMed Central

28 July 2017

William G Nelson

4

1 reference

Europe PubMed Central

28 July 2017

Helen Fedor

5

1 reference

Europe PubMed Central

28 July 2017

Marianna L Zahurak

7

1 reference

Europe PubMed Central

28 July 2017

Andrew J Dannenberg

9

1 reference

Europe PubMed Central

28 July 2017

Robin T Gurganus

10

1 reference

Europe PubMed Central

28 July 2017

Howard L Parnes

12

1 reference

Europe PubMed Central

28 July 2017

Theodore L DeWeese

13

1 reference

Europe PubMed Central

28 July 2017

Michael A Carducci

15

1 reference

Europe PubMed Central

28 July 2017

language of work or name

0 references

publication date

31 August 2009

1 reference

Europe PubMed Central

28 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

28 July 2017

27

1 reference

Europe PubMed Central

28 July 2017

4986-4993

1 reference

Europe PubMed Central

28 July 2017

30

1 reference

Europe PubMed Central

28 July 2017

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

COX-2 inhibition: a possible role in the management of prostate cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Celecoxib for the prevention of sporadic colorectal adenomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Quantitative assessment of seminal vesicle and prostate drug concentrations by use of a noninvasive method

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Targeting cyclooxygenase-2 in human neoplasia: rationale and promise

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

8-Hydroxyguanosine repair is defective in some microsatellite stable colorectal cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Tissue microarray sampling strategy for prostate cancer biomarker analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Risk of cardiovascular events associated with selective COX-2 inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Unique features of the basal cells of human prostate epithelium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

A blood-prostate barrier restricts cell and molecular movement across the rat ventral prostate epithelium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Models for longitudinal data: a generalized estimating equation approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

21 June 2018

Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

31 October 2018

Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

31 October 2018

Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

31 October 2018

The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

31 October 2018

Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

31 October 2018

Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799055

31 October 2018

Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19720908

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19720908

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19720908

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19720908

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

1 reference

https://pubmed.ncbi.nlm.nih.gov/19720908

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19720908

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19720908

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.21.9410

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33561179&oldid=1979065122"